Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Feature|Articles|June 30, 2026
5 urologic oncology headlines you missed in Q2 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A roundup of the key stories across genitourinary cancers from the second quarter of 2026.
Advertisement
Advertisement
The second quarter of 2026 brought several practice-changing developments across genitourinary oncology, from new FDA approvals to pivotal phase 3 data presented at major scientific meetings. Advances in bladder, prostate, and kidney cancer expanded treatment options in both the adjuvant and perioperative settings while highlighting the growing role of biomarker-guided care and combination strategies.
Related to this article
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Advertisement
Advertisement